After A Decade Of US Biosimilars, ‘The Challenges Are Becoming More Clear’
Biosimilars Council Chief Craig Burton Discusses Progress And The Road Ahead
As the US marks 10 years since the first biosimilar approval and launch, AAM Biosimilars Council executive director Craig Burton talks to Generics Bulletin about the lessons learned so far and the path ahead, including how to move on from market models that have proved to be “not appropriate” for biosimilars.
